Moderna has just delivered a striking example of how medical science can move financial markets. Its shares surged 177 percent in a single session after a personalised mRNA cancer treatment succeeded in a phase 3 trial. But what exactly did investors see, and does every medical breakthrough translate into a stock-market jackpot?
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
&im=FitAndFill=(700,400)?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)
?&imwidth=252&imheight=189)